Immunome (IMNM) Change in Accured Expenses (2019 - 2026)

Immunome (IMNM) has 8 years of Change in Accured Expenses data on file, last reported at -$9.7 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 14.38% year-over-year to -$9.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (down 24.13% YoY) and the FY2025 annual result came in at $4.5 million, down 66.55% from the prior year.
• Change in Accured Expenses slipped to -$9.7 million in Q1 2026, from $5.7 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $6.9 million in Q2 2024 to a low of -$9.7 million in Q1 2026.
• A 5-year average of $413470.6 and a median of $619000.0 in 2025 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 13155.81% in 2025, down 1373.69% in 2025.
• Tracing IMNM's Change in Accured Expenses over 5 years: stood at $549000.0 in 2022, then jumped by 276.32% to $2.1 million in 2023, then sank by 97.92% to $43000.0 in 2024, then surged by 13155.81% to $5.7 million in 2025, then sank by 270.98% to -$9.7 million in 2026.
• The last three Change in Accured Expenses figures came in at -$9.7 million (Q1 2026), $5.7 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.